Physician profile
Phillip Tran
NPI 1376983817
$1,996.26
in general payments reported to CMS, 2019-2025
14 companies · $41.53 in 2025
The $41.53 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $72.13 · 2021: $122 · 2022: $149 · 2023: $279 · 2024: $315 · 2025: $41.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Artivion, INC. | $515.51 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $301.09 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $261.86 | 2019-2023 | Eliquis, Camzyos |
| Amgen INC. | $210.33 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $196.33 | 2019-2023 | |
| Abbott Laboratories | $146.91 | 2019-2024 | Cardiomems |
| Medtronic, INC. | $122.00 | 2021 | |
| Boston Scientific Corporation | $105.23 | 2019-2024 | Watchman |
| Janssen Pharmaceuticals, INC | $53.68 | 2019-2023 | Xarelto |
| Pfizer INC. | $31.21 | 2019 | |
| Philips North America LLC | $14.46 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.20 | 2023 | Farxiga |
| Cook Medical LLC | $12.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.